Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Uncomplicated Urinary Tract Infection Market Size During 2025–2029?
The uncomplicated urinary tract infection market size has experienced strong growth in recent years. It is forecast to expand from $10.24 billion in 2024 to $10.95 billion in 2025, progressing at a compound annual growth rate (CAGR) of 6.9%. The market’s past development was driven by an increase in cases of renal failure, a rise in bladder cancer occurrences, the growing incidences of chronic kidney diseases, greater utilization of urinary catheters, and an expanding prevalence of diabetes.
The market for uncomplicated urinary tract infections is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $14.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this growth during the projected period include a rise in bacterial infections, a growing aging demographic, increased sexual activity, a surge in urinary tract infection cases, and the expanded use of contraceptives. Key trends anticipated within the forecast timeframe encompass the evolution of telemedicine, improvements in telehealth solutions, the creation of new drugs, progress in urinary tract infection treatments, and advancements in research and development efforts.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23550&type=smp
What Are The Top Growth Drivers Impacting The Uncomplicated Urinary Tract Infection Market Outlook?
The rising incidence of chronic kidney diseases is anticipated to propel the uncomplicated urinary tract infection market. Chronic kidney disease (CKD) is a progressive condition where the kidneys gradually lose functionality, leading to an accumulation of waste and fluids in the body. The increasing cases of CKD are attributed to the growing prevalence of diabetes, as prolonged high blood sugar levels can damage the kidneys and diminish their capacity to filter waste effectively. Moreover, CKD compromises the immune system, making individuals more vulnerable to urinary tract infections, and impaired kidney function results in urine retention, which fosters an environment for bacterial growth. For instance, according to Kidney Research UK, a UK-based charity, the number of adults receiving kidney transplants in the United Kingdom due to chronic kidney disease increased from 2,863 transplants in 2021 to 2,976 in 2023, as reported in June 2023. Consequently, the escalating incidence of chronic kidney diseases will drive the uncomplicated urinary tract infection market.
What Are The Segment Types Shaping The Uncomplicated Urinary Tract Infection Market?
The uncomplicated urinary tract infectionmarket covered in this report is segmented –
1) By Test Type: Urinalysis; Urine Cultures; Susceptibility Testing
2) By Drug: Penicillin And Combinations; Quinolones; Cephalosporin; Azoles And Amphotericin B; Nitrofurans; Other Drugs
3) By End-Users: Hospitals; Diagnostic Labs; Research Institutes
Subsegments:
1) By Urinalysis: Dipstick Tests; Microscopic Examination; Automated Urinalysis
2) By Urine Cultures: Agar Plate Culture; Broth Culture; Chromogenic Media
3) By Susceptibility Testing: Disk Diffusion Method; Automated Susceptibility Testing; Molecular Susceptibility Testing
What Trends Are Redefining The Uncomplicated Urinary Tract Infection Market Dynamics?
Key companies operating within the uncomplicated urinary tract infection (UTI) market are concentrating on developing new antibiotics to enhance treatment effectiveness and address antibiotic-resistant bacteria. Antibiotics function as medications that combat bacterial infections by either eliminating or impeding the growth of bacteria in the body. For instance, in April 2024, the Food and Drug Administration, a federal agency based in the US, granted approval for Pivya (pivmecillinam) tablets for use in treating adult females with uncomplicated urinary tract infections. This tablet is specifically formulated for uncomplicated urinary tract infections caused by susceptible Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus isolates. Pivmecillinam serves as a prodrug that converts into mecillinam, a beta-lactam antibiotic designed to target gram-negative bacteria by inhibiting the synthesis of their cell walls.
Who Are The Top Performing Companies In The Uncomplicated Urinary Tract Infection Market In Recent Years?
Major companies operating in the uncomplicated urinary tract infection market are Cardinal Health, Pfizer Inc., Bayer AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Siemens AG, Strykar Healthcare, John Hopkins Medicine, Shionogi & Co. Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc, Cipla Inc., UTILITY therapeutics Ltd, Orchid Pharma Limited, ACON Labs, Sonika Lifesciences, Emergency Care BC, EB Medicine, Iterum Therapeutics PLC
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Uncomplicated Urinary Tract Infection Market Outlook?
North America was the largest region in the uncomplicated urinary tract infection market in 2024. The regions covered in the uncomplicated urinary tract infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Uncomplicated Urinary Tract Infection Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23550&type=smp
Browse Through More Reports Similar to the Global Uncomplicated Urinary Tract Infection Market 2025, By The Business Research Company
Pharmaceutical Drugs And Biologics Logistics Market 2025
Urinary Incontinence And Pelvic Organ Prolapse Devices And Equipment Global Market Report 2025
Urinary Stone Treatment Devices And Equipment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model